Media coverage
17
Media coverage
Title Opdivo® (nivolumab) in Combination with CABOMETYX® (cabozantinib) Shows Durable Survival with Over Three Years of Follow-Up in the CheckMate -9ER Trial in First-Line Advanced Renal Cell Carcinoma Media name/outlet PharmiWeb Country/Territory United Kingdom Date 14/02/23 URL ct.moreover.com/?a=50002124222&p=1gw&v=1&x=ZIWDI3CWxaVq3S6r6tDO1Q Persons Mauricio Burotto Title Opdivo® (nivolumab) in Combination with CABOMETYX® (cabozantinib) Shows Durable Survival with Over Three Years of Follow-Up in the CheckMate -9ER Trial in First-Line Advanced Renal Cell Carcinoma Media name/outlet Morningstar.com Country/Territory United States Date 13/02/23 URL ct.moreover.com/?a=50001108602&p=1gw&v=1&x=HYcu4pzzYxGSruHaR8oQkw Persons Mauricio Burotto Title Opdivo® (nivolumab) in Combination with CABOMETYX® (cabozantinib) Shows Durable Survival with Over Three Years of Follow-Up in the CheckMate -9ER Trial in First-Line Advanced Renal Cell Carcinoma Media name/outlet Street Insider Country/Territory United States Date 13/02/23 URL ct.moreover.com/?a=50001104705&p=1gw&v=1&x=xTr1OjLklFZ5FXq2RDGvNw Persons Mauricio Burotto Title Exelixis (EXEL) and Bristol Myers Squibb (BMY) Reports Strong Results from Phase 3 CheckMate-9ER Trial Media name/outlet Street Insider Country/Territory United States Date 13/02/23 URL ct.moreover.com/?a=50001126436&p=1gw&v=1&x=WzsEPQHOB1m6XihGBI4clA Persons Mauricio Burotto Title Opdivo® (nivolumab) in Combination with CABOMETYX® (cabozantinib) Shows Durable Survival with Over Three Years of Follow-Up in the CheckMate -9ER Trial in First-Line Advanced Renal Cell Carcinoma Media name/outlet BioSpace Country/Territory United States Date 13/02/23 URL ct.moreover.com/?a=50001479639&p=1gw&v=1&x=_gYGsRy5SOL_L-pIgBJR1g Persons Mauricio Burotto Title Opdivo® (nivolumab) in Combination with CABOMETYX® (cabozantinib) Shows Durable Survival with Over Three Years of Follow-Up in the CheckMate -9ER Trial in First-Line Advanced Renal Cell Carcinoma Media name/outlet InvestorsObserver Country/Territory United States Date 13/02/23 URL ct.moreover.com/?a=50001104969&p=1gw&v=1&x=mnCanpDHb5HDcV3kov1BVQ Persons Mauricio Burotto Title Opdivo® (nivolumab) in Combination with CABOMETYX® (cabozantinib) Shows Durable Survival with Over Three Years of Follow-Up in the CheckMate -9ER Trial in First-Line Advanced Renal Cell Carcinoma Media name/outlet Yahoo! Finance Country/Territory United States Date 13/02/23 URL ct.moreover.com/?a=50001166795&p=1gw&v=1&x=aDZf0Bmk9Erwf7osWifRAQ Persons Mauricio Burotto Title Opdivo® (nivolumab) in Combination with CABOMETYX® (cabozantinib) Shows Durable Survival with Over Three Years of Follow-Up in the CheckMate -9ER Trial in First-Line Advanced Renal Cell Carcinoma Media name/outlet MarketScreener.com Country/Territory United States Date 13/02/23 URL ct.moreover.com/?a=50001099441&p=1gw&v=1&x=9pKOaQgTs_NJBqVScu0cuA Persons Mauricio Burotto Title Opdivo ‚ ® (nivolumab) in Combination with CABOMETYX ‚ ® (cabozantinib) Shows Durable Survival with Over Three Years of Follow-Up in the CheckMate -9ER Trial in First-Line Advanced Renal Cell Carcinoma Media name/outlet Stockwatch Country/Territory Canada Date 13/02/23 URL ct.moreover.com/?a=50001101890&p=1gw&v=1&x=mwYjQ6x-ZEmBPDfEleIeAQ Persons Mauricio Burotto Title Opdivo® (nivolumab) in Combination with CABOMETYX® (cabozantinib) Shows Durable Survival with Over Three Years of Follow-Up in the CheckMate -9ER Trial in First-Line Advanced Renal Cell Carcinoma Media name/outlet Market Newsdesk Country/Territory United States Date 13/02/23 URL ct.moreover.com/?a=50001106162&p=1gw&v=1&x=ItTVK10_olye4Wv1Z1GkTA Persons Mauricio Burotto Title Opdivo® (nivolumab) in Combination with CABOMETYX® (cabozantinib) Shows Durable Survival with Over Three Years of Follow-Up in the CheckMate -9ER Trial in First-Line Advanced Renal Cell Carcinoma Media name/outlet Le Lezard.com Country/Territory Canada Date 13/02/23 URL ct.moreover.com/?a=50001113379&p=1gw&v=1&x=YLxo3YNAslT4Z0pzj3kgTQ Persons Mauricio Burotto Title Opdivo® (nivolumab) in Combination with CABOMETYX® (cabozantinib) Shows Durable Survival with Over Three Years of Follow-Up in the CheckMate -9ER Trial in First-Line Advanced Renal Cell Carcinoma Media name/outlet Spoke.com Country/Territory United States Date 13/02/23 URL ct.moreover.com/?a=50001324672&p=1gw&v=1&x=-oG5LCWqKpwA5uvs6TnC_w Persons Mauricio Burotto Title Opdivo® (nivolumab) in Combination with CABOMETYX® (cabozantinib) Shows Durable Survival with Over Three Years of Follow-Up in the CheckMate -9ER Trial in First-Line Advanced Renal Cell Carcinoma Media name/outlet CIT Country/Territory United States Date 13/02/23 URL ct.moreover.com/?a=50001103336&p=1gw&v=1&x=c843yRHbw7YDvE-8TGfYaA Persons Mauricio Burotto Title Opdivo® (nivolumab) in Combination with CABOMETYX® (cabozantinib) Shows Durable Survival with Over Three Years of Follow-Up in the CheckMate -9ER Trial in First-Line Advanced Renal Cell Carcinoma Media name/outlet Business Wire Country/Territory United States Date 13/02/23 URL ct.moreover.com/?a=50001165145&p=1gw&v=1&x=XmMtBob50YfrGMB3IK3uZQ Persons Mauricio Burotto Title Opdivo® (nivolumab) in Combination with CABOMETYX® (cabozantinib) Shows Durable Survival with Over Three Years of Follow-Up in the CheckMate -9ER Trial in First-Line Advanced Renal Cell Carcinoma; Data to be featured at ASCO GU 2023 demonstrate continued Media name/outlet Business Wire Country/Territory United States Date 13/02/23 URL ct.moreover.com/?a=50001204546&p=1gw&v=1&x=uT1YkWOlF_ojIiv9yuX3Yw Persons Mauricio Burotto Title Opdivo® (nivolumab) in Combination with CABOMETYX® (cabozantinib) Shows Durable Survival with Over Three Years of Follow-Up in the CheckMate -9ER Trial in First-Line Advanced Renal Cell Carcinoma Media name/outlet Bakersfield.com Country/Territory United States Date 13/02/23 URL ct.moreover.com/?a=50001309814&p=1gw&v=1&x=lTwKLBKELZSadSX2mOj6FA Persons Mauricio Burotto Title Opdivo® (nivolumab) in Combination with CABOMETYX® (cabozantinib) Shows Durable Survival with Over Three Years of Follow-Up in the CheckMate -9ER Trial in First-Line Advanced Renal Cell Carcinoma Media name/outlet VB Profiles Country/Territory United States Date 13/02/23 URL ct.moreover.com/?a=50001304583&p=1gw&v=1&x=Dz5RrTpV7vWxxR_JpbrFNA Persons Mauricio Burotto